Cancer Letters
Volume 262, Issue 2 , Pages 143-152 , 18 April 2008

Boron neutron capture therapy for glioblastoma

Received 19 November 2007 ,Revised 11 January 2008 ,Accepted 14 January 2008.

References 

  1. Gasper LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int. J. Radiat. Oncol. Biol. Phys. 1992;24:55–57
  2. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Malkin MG: patterns of failure following treatment for glioblastoma multiform and anaplastic astrocytoma. J. Radiat. Oncol. Biol. Phys. 1989;16:1405–1409
  3. Oppitz U, Maessen D, Zunterer H, Richter S. Flentje M: 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother. Oncol. 1999;53:53–57
  4. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomized controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401
  5. Nimsky C, Ganslandt O, von Keller B, Fahlbusch R. Intraoperative visualization for resection of gliomas: the role of functional neuronavigation and intraoperative 1.5 T MRI. Neurol. Res. 2006;28:482–487
  6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352:987–996
  7. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: cooperative clinical trial. J. Neurosurg. 1978;49:333–343
  8. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 1980;303:1323–1329
  9. Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV: confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981;47:649–652
  10. Sandberg-Wollheim M, Malmstrom P, Stromblad LG, et al. A randomized study of chemotherapy with procarbazine, vincristine, and the lomustine with and without radiation therapy for astrocytoma grade 3 and/or 4. Cancer. 1991;68:22–29
  11. Anderson AP. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radio Oncol. Radiat. Phys. Biol. 1978;17:475–484
  12. Bleehen NM, Stennning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br. J. Cancer. 1991;64:769–774
  13. Fitzek MM, Thornton AF, Rabinov JD, Lev MH, Pardo FS, Munzenrider JE, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J. Neurosurg. 1999;91:251–260
  14. Tanaka M, Ino Y, Nakagawa k, Tago M, Todo T. High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. Lancet Oncol. 2005;6:953–960
  15. Nwokedi EC, DiBase SJ, Jabbour S, Herman J, Amin P, Chin LS. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery. 2002;50:41–47
  16. Baumert BG, Lutterbach J, Bernays R, Davis JB, Heppner FL. Fractionated stereotactic radiotherapy boost after post-operative radiotherapy in patients with high-grade gliomas. Radiother. Oncol. 2003;67:183–190
  17. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of RadiationTherapy Oncology Group 93-05 protocol. Int. J. Radiat. Oncol. Biol. Phys. 2004;60:853–860
  18. Chanana AD, Capala J, Chadha M, Coderre JA, Diaz AZ, Elowitz EH, et al. Boron neutron capture therapy for glioblastoma multiforme: interim results from the Phase I/II dose-escalation studies. Neurosurgery. 1999;44:1182–1193
  19. Mishima Y. Melanoma and non-melanoma neutron capture therapy using gene therapy: overview. In:  Larsson B,  Crawford J,  Weinreich R editor. Advances in Neutron Capture Therapy. Medicine and Physics, Excerpta Medica ICS 1132. Amsterdam: Elsevier; 1997;p. 10–25vol. I
  20. Mishima Y, Kondhok H. Dual control of melanogenesis and melanoma growth: overview molecular to clinical level and the reverse. Pigm. Cell Res. 2000;13(Suppl. 8):10–22
  21. Tamura Y, Miyatake S, Nonoguchi N, Miyata S, Yokoyama K, Doi A, et al. Boron neutron capture therapy for recurrent malignant meningioma. Case report. J. Neurosurg. 2006;105:898–903
  22. Stenstam BH, Pellettieri L, Sorteberg W, Rezaei A, Skold K. BNCT for recurrent intracranial meningeal tumours – case reports. Acta Neurol. Scand. 2007;115:243–247
  23. Kankaanranta L, Seppälä T, Koivunoro H, Saarilahti K, Atula T, Collan J, et al. Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007;69:475–482
  24. Wittig A, Malago M, Collette L. Uptake of two 10B-compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001). Int. J. Cancer. 2008;122:1164–1171
  25. Suzuki M, Sakurai Y, Hagiwara S. First attempt of boron neutron capture therapy (BNCT) for hepatocellular carcinoma. Jpn. J. Clin. Oncol. 2007;37:376–381
  26. Locher GL. Biological effects and therapeutic possibilities of neutrons. Am. J. Roentgenol. 1936;36:1–13
  27. Farr LE, Sweet WH, Robertson JS, Foster CG, Locksley HB, Sutherland L, et al. Neutron capture therapy with boron in the treatment of glioblastoma multiforme. Am. J. Roentgenol. 1954;71:279–293
  28. Farr LE, Haymaker W, Konikowski T, Lippincott W. Effects of alpha particles randomly induced in the brain in the neutron-capture treatment of intracranial neoplasm. Int. J. Neurol. 1962;3:564–576
  29. Sweet WH, Soloway AH, Brownell GL. Boron-slow neutron capture therapy of gliomas. Acta Radiol. 1963;1:114–1121
  30. Sweet WH. Early history of development of boron neutron capture therapy of tumors. J. Neurooncol. 1997;33:19–26
  31. Nakagawa Y, Hatanaka H. Boron neutron capture therapy: clinical brain tumor studies. J. Neurooncol. 1997;33:105–115
  32. Slatkin DN. A history of boron neutron capture therapy of brain tumours. Postulation of a brain radiation dose tolerance limit. Brain. 1991;114:1609–1629
  33. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group Malignant Glioma Trials. J. Natl. Cancer Inst. 1993;85:704–710
  34. Laramore GE, Spence AM. Boron neutron capture therapy (BNCT) for high grade gliomas of the brain: A cautionary note. Int. J. Radiat. Oncol. Biol. Phys. 1996;36:241–246
  35. Yamamoto T, Matsumura A, Nakai K, Shibata Y, Endo K, Sakurai F, et al. Current clinical results of the Tsukuba BNCT trial. Appl. Radiat. Isot. 2004;61:1089–1093
  36. Witig A, Hideghety K, Paquis P, et al. Current clinical results of the EORTC-study 11961. In:  Surewein W,  Moss R,  Wittig A editor. Research and Development in Neutron Capture Therapy. Bologna: Monduzzi Editore; 2002;p. 1117–1122
  37. Capala JH, Stenstam BH, Sköld K, et al. Boron neutron capture therapy for glioblastoma multiforme. J. Neurooncol. 2003;62:135–144
  38. Miyatake S, Kajimoto Y, Kawabata S, et al. Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J. Neurosurg. 2005;103:1000–1009
  39. L. Kankaanranta, M. Kulvik, T. Seppälä, et al., BPA mediated BNCT in gliomas in FiR 1, Abstract of the 11th World Congress on Neutron Capture Therapy, 2004 October 11–15, Boston, MA, p. 6.
  40. Burian J, Marek M, Rataj J, et al. Report on the first group of the phase I BNCT trial at the LVR-15 reactor. In:  Surewein W,  Moss R,  Wittig A editor. Research and Development in Neutron Capture Therapy. Bologna: Monduzzi Editore; 2002;p. 1107–1112
  41. Busse PM, Harling OK, Palmer MR, Kiger WS, Kaplan J, Kaplan I, et al. A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J. Neurooncol. 2003;62:111–121
  42. Diaz AZ. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician’s point of view. J. Neurooncol. 2003;62:101–109
  43. Coderre JA, Hopewell JW, Turcottea JC, Rileyc KJ, Binnsc PJ, et al. Tolerance of normal human brain to boron neutron capture therapy. Appl. Radiat. Isot. 2004;61:1083–1087
  44. Kageji T, Nagahiro S, Matsuzaki K, Mizobuchi Y, Toi H, Nakagawa Y, et al. Boron neutron capture therapy using mixed epithermal and thermal neutron beams in patients with malignant glioma-correlation between radiation dose and radiation injury and clinical outcome. Int. J. Radiat. Oncol. Biol. Phys. 2006;65:1446–1455
  45. Nakagawa Y, Pooh K, Kobayashi T, et al. Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams. J. Neurooncol. 2003;62:87–99
  46. Joel DD, Coderre JA, Micca PL, Nawrocky MM. Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy. J. Neurooncol. 1999;41:213–221
  47. Smith D, Chandra S, Barth R, Yang W, Joel D, Coderre JA. Quantitative imaging and microlocalization of boron-10 in brain tumors and infiltrating tumor cells by SIMS ion microscopy: relevance to neutron capture therapy. Cancer Res. 2001;61:8179–8187
  48. Yoshida F, Matsumura A, Shibata Y, Yamamoto T, Nakauchi H, Okumura M, et al. Cell cycle dependence of boron uptake from two boron compounds used for clinical neutron capture therapy. Cancer Lett. 2002;187:135–141
  49. Barth RF, Grecula JC, Yang W, et al. Combination of boron neutron capture therapy and external beam radiotherapy for brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 2004;58:267–277
  50. Soloway AH, Hatanaka H, Davis MA. Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds. J. Med. Chem. 1967;10:714–747
  51. Hideghety K, Sauerwein W, Wittig A, Gotz C, Paquis P, Grochulla F, et al. Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial. J. Neurooncol. 2003;62(1-2):145–156
  52. Kraft SL, Gavin PR, Leathers CW, DeHaan CE, Bauer WF, et al. Biodistribution of boron in dogs with spontaneous intracranial tumors following borocaptate sodium administration. Cancer Res. 1994;54:1259–1263
  53. Barth RF, Yang W, Rotaru JH, et al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood–brain barrier disruption. Cancer Res. 1997;57:1129–1136
  54. Fukuda H, Hiratsuka J, Honda C, Kobayashi T, Yoshino K, Karashima H, et al. Boron neutron capture therapy of malignant melanoma using 10B-paraboronophenylalanine with special reference to evaluation of radiation dose and damage to the skin. Radiat. Res. 1994;138:435–442
  55. Ono K, Masunaga SI, Kinashi Y, Takagaki M, Akaboshi M, Kobayashi T, et al. Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy. Int. J. Radiat. Oncol. Biol. Phys. 1996;34:1081–1086
  56. Isaac MF, Kahl SB. Synthesis of ether- and carbonlinked polycarboranyl porphyrin dimers for cancer therapies. J. Organomet. Chem. 2003;680:232–243
  57. Ceberg CP, Brun A, Kahl SB, Koo MS, Persson BR, Salford LG. A comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model. J. Neurosurg. 1995;83:86–92
  58. Kabalka GW, Yao M-L. Synthesis of a potential boron neutron capture therapy agent: 1-aminocyclobutane-1-carboxylic acid bearing a butylboronic acid side chain. Synthesis. 2003;18:2890–2893
  59. Diaz A, Stelzer K, Laramore G, Wiersema R. Pharmachology studies of Na2B10H10 (GB-10) in human tumor patients. In:  Surewein W,  Moss R,  Wittig A editor. Research and Development in Neutron Capture Therapy. Bologna: Monduzzi Editore; 2002;p. 993–999
  60. Tietze LF, Griesbach U, Schuberth I, Bothe U, Marra A, Dondoni A. Novel carboranyl C-glycosides for the treatment of cancer by boron neutron capture therapy. Chem. Eur. J. 2003;9(6):1296–1302
  61. El-Zaria ME, Doerfler U, Gabel D. Synthesis of [(aminoalkylamine)-n-aminoalkyl] azanonaborane(11) derivatives for boron neutron capture therapy. J. Med. Chem. 2002;45:5817–5819
  62. Tjarks W. The use of boron clusters in the rational design of boronated nucleosides for neutron capture therapy of cancer. J. Organomet. Chem. 2001;614-615:37–47
  63. Al-Madhoun AS, Johnsamuel J, Yan J, et al. Synthesis of a small library of 3-(carboranylalkyl) thymidinesan d their biological evaluation as substrates for human thymidine kinases 1 and 2. J. Med. Chem. 2002;45:4018–4028
  64. Tietze LF, Griesbach U, Bothe U, Nakamura H, Yamamoto Y. Novel carboranes with a DNA binding unit for the treatment of cancer by boron neutron capture therapy. Chembiochem. 2002;3:219–225
  65. Woodhouse SL, Rendina LM. Synthesis and DNA binding properties of dinuclear platinum(II)-amine complexes of 1,7-dicarba-closo-dodecaborane(12). Chem. Commun. 2001;2464–2465
  66. Olejiniczak AB, Koziolkiewcz M, Lesnikowski ZJ. Carboranyl oligonucleotides: 4. Synthesis and physicochemical studies of oligonucleotides containing 20-O-(o-carboran-1-yl)methyl group. Antisense Nucleic Acid Drug Dev. 2002;12:79–94
  67. Ivanov D, Bachovchin WW, Redfield AG. Boron-11 pure quadrupole resonance investigation of peptide boronic acid inhibitors bound to a-lyticprotease. Biochemistry. 2002;41:1587–1590
  68. Carlsson J, Kullberg EB, Capala J, et al. Ligand liposomes and boron neutron capture therapy. J. Neurooncol. 2003;62:47–59
  69. Justus E, Awad D, Hohnholt M, Schaffran T, Edwards K, Karlsson G, et al. Synthesis, liposomal preparation, and in vitro toxicity of two novel dodecaborate cluster lipids for boron neutron capture therapy. Bioconjug. Chem. 2007;18(4):1287–1293
  70. Nakamura H, Miyajima Y, Takei T, Kasaoka S, Maruyama K. Synthesis and vesicle formation of a nidocarborane cluster lipid for boron neutron capture therapy. Chem. Commun. (Cambridge, UK). 2004;1910–1911
  71. Olsson P, Gedda L, Goike H, et al. Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without human EGF-receptor expression. Anticancer Drug Des. 1998;13:279–289
  72. Coderre JA, Turcotte JC, Riley KJ, Binns PJ, Harling OK. Kiger III, W.S. Boron neutron capture therapy: cellular targeting of high linear energy transfer radiation. Technol. Cancer Res. Treatment. 2003;5:1–21
  73. Rosental M, Kavar B, Hill J, Morgan D, Nation R, Stylli S, et al. Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin. J. Clin. Oncol. 2001;19:519–524
  74. Hao E, Jensen TJ, Courtney BH, Vicente MG. Synthesis and cellular studies of porphyrin–cobaltacarborane conjugates. Bioconjug. Chem. 2005;16(6):1495–1502
  75. Friso E, Roncucci G, Dei D, Soncin M, Fabris C, Chiti G, et al. A novel 10B-enriched carboranyl-containing phthalocyanine as a radio- and photo-sensitising agent for boron neutron capture therapy and photodynamic therapy of tumours: in vitro and in vivo studies. Photochem. Photobiol. Sci. 2006;5(1):39–50
  76. Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, et al. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II. Clin. Cancer Res. 1998;4(8):1833–1841
  77. Culbertson CN, Green S, Mason AJ, Picton D, Baugh G, Hugtenburg RP, et al. In-phantom characterization studies at the Birmingham Accelerator-Generated epIthermal Neutron Source (BAGINS) BNCT facility. Appl. Radiat. Isot. 2004;61:733–738

PII: S0304-3835(08)00044-X

doi: 10.1016/j.canlet.2008.01.021

Cancer Letters
Volume 262, Issue 2 , Pages 143-152 , 18 April 2008

Article Tools

* Image Usage & Resolution